메뉴 건너뛰기




Volumn 9, Issue 2, 2015, Pages 134-138

Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

Author keywords

cancer; drug resistance; receptor tyrosine kinases; targeted therapy

Indexed keywords

PROTEIN TYROSINE KINASE;

EID: 84974604173     PISSN: 20950217     EISSN: 20950225     Source Type: Journal    
DOI: 10.1007/s11684-015-0396-9     Document Type: Review
Times cited : (41)

References (30)
  • 1
    • 44849093562 scopus 로고    scopus 로고
    • Oncogene addiction
    • COI: 1:CAS:528:DC%2BD1cXltlSmtrk%3D, PID: 18451130
    • Weinstein IB, Joe A, Felsher D. Oncogene addiction. Cancer Res 2008; 68(9): 3077–3080, discussion 3080
    • (2008) Cancer Res , vol.68 , Issue.9 , pp. 3070-3077
    • Weinstein, I.B.1    Joe, A.2    Felsher, D.3
  • 2
    • 9244222261 scopus 로고    scopus 로고
    • Targeted cancer therapy
    • COI: 1:CAS:528:DC%2BD2cXpvVCjtL8%3D, PID: 15549090
    • Sawyers C. Targeted cancer therapy. Nature 2004; 432(7015): 294–297
    • (2004) Nature , vol.432 , Issue.7015 , pp. 294-297
    • Sawyers, C.1
  • 3
    • 77953896432 scopus 로고    scopus 로고
    • Cell signaling by receptor tyrosine kinases
    • COI: 1:CAS:528:DC%2BC3cXovFartb0%3D, PID: 20602996
    • Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141(7): 1117–1134
    • (2010) Cell , vol.141 , Issue.7 , pp. 1117-1134
    • Lemmon, M.A.1    Schlessinger, J.2
  • 4
    • 84887497121 scopus 로고    scopus 로고
    • The quest to overcome resistance to EGFRtargeted therapies in cancer
    • COI: 1:CAS:528:DC%2BC3sXhslCmsLrP, PID: 24202392
    • Chong CR, Jänne PA. The quest to overcome resistance to EGFRtargeted therapies in cancer. Nat Med 2013; 19(11): 1389–1400
    • (2013) Nat Med , vol.19 , Issue.11 , pp. 1389-1400
    • Chong, C.R.1    Jänne, P.A.2
  • 5
    • 84884535896 scopus 로고    scopus 로고
    • Cancer drug resistance: an evolving paradigm
    • COI: 1:CAS:528:DC%2BC3sXhsVyqurnE, PID: 24060863
    • Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13(10): 714–726
    • (2013) Nat Rev Cancer , vol.13 , Issue.10 , pp. 714-726
    • Holohan, C.1    Van Schaeybroeck, S.2    Longley, D.B.3    Johnston, P.G.4
  • 6
    • 84890018871 scopus 로고    scopus 로고
    • Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
    • COI: 1:CAS:528:DC%2BC3sXhvVGrtrfE, PID: 24101047
    • Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013; 31(31): 3987–3996
    • (2013) J Clin Oncol , vol.31 , Issue.31 , pp. 3987-3996
    • Gainor, J.F.1    Shaw, A.T.2
  • 7
    • 84913536390 scopus 로고    scopus 로고
    • Drug resistance to targeted therapies: déjà vu all over again
    • COI: 1:CAS:528:DC%2BC2cXhtVWrs7jP, PID: 24910388
    • Groenendijk FH, Bernards R. Drug resistance to targeted therapies: déjà vu all over again. Mol Oncol 2014; 8(6): 1067–1083
    • (2014) Mol Oncol , vol.8 , Issue.6 , pp. 1067-1083
    • Groenendijk, F.H.1    Bernards, R.2
  • 8
    • 84922781885 scopus 로고    scopus 로고
    • Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
    • COI: 1:CAS:528:DC%2BC2cXhsV2ktLrF, PID: 25239057
    • Sun C, Bernards R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci 2014; 39(10): 465–474
    • (2014) Trends Biochem Sci , vol.39 , Issue.10 , pp. 465-474
    • Sun, C.1    Bernards, R.2
  • 14
    • 84885816283 scopus 로고    scopus 로고
    • Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer
    • PID: 24065147
    • Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal 2013; 6(294): re6
    • (2013) Sci Signal , vol.6 , Issue.294 , pp. re6
    • Niederst, M.J.1    Engelman, J.A.2
  • 17
    • 0035915421 scopus 로고    scopus 로고
    • Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
    • COI: 1:CAS:528:DC%2BD38XltVWluw%3D%3D, PID: 11752009
    • Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93(24): 1852–1857
    • (2001) J Natl Cancer Inst , vol.93 , Issue.24 , pp. 1852-1857
    • Lu, Y.1    Zi, X.2    Zhao, Y.3    Mascarenhas, D.4    Pollak, M.5
  • 25
    • 84883793323 scopus 로고    scopus 로고
    • RON confers lapatinib resistance in HER2-positive breast cancer cells
    • COI: 1:CAS:528:DC%2BC3sXhtFSmtrfK, PID: 23811285
    • Wang Q, Quan H, Zhao J, Xie C, Wang L, Lou L. RON confers lapatinib resistance in HER2-positive breast cancer cells. Cancer Lett 2013; 340(1): 43–50
    • (2013) Cancer Lett , vol.340 , Issue.1 , pp. 43-50
    • Wang, Q.1    Quan, H.2    Zhao, J.3    Xie, C.4    Wang, L.5    Lou, L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.